The study of development trends of the pharmaceutical market of neuroprotective drugs in Ukraine

A A Kotvitska,I O Lobova

doi:10.24959/sphhcj.15.21

Abstract

The main trends in the development of the pharmaceutical market of neuroprotective action drugs in Ukraine over the past five years have been investigated in the article. Also the analysis of indicators in sales of neuroprotective action drugs in natural and monetary units. An important aspect of the work is to determine the ratio of consumption of neuroprotective medications of domestic and foreign production within each pharmacotherapeutic group of medicines.

Highlights

The main trends in development of the pharmaceutical market of drugs with the neuroprotective action in Ukraine over the past five years have been studied in the article
The research conducted showed that the Ukrainian neuroprotective drugs (ND) market sales volume in 2014 was 1.89 billion Ukrainian Hryvnias (UAH) for 23 797 886 packages, it increased by 22.22% in monetary value compared to 2010 and significantly decreased in natural units
The analysis has shown that the demand for ND of the pharmacotherapeutic group C, which includes seven subgroups, for the period of 2010-2014 in natural units is higher in subgroups of inosine and pentoxifylline (Table 2)

Summary

СОЦІАЛЬНИЙ МАРКЕТИНГ ТА ФАРМАКОЕКОНОМІЧНІ

THE STUDY OF DEVELOPMENT TRENDS OF THE PHARMACEUTICAL MARKET OF NEUROPROTECTIVE DRUGS IN UKRAINE. The research conducted showed that the Ukrainian ND market sales volume in 2014 was 1.89 billion Ukrainian Hryvnias (UAH) for 23 797 886 packages, it increased by 22.22% in monetary value compared to 2010 and significantly decreased (by 26.22%) in natural units. During analysis of the pharmacotherapeutic structure of the ND consumption it has been found that the most extensive cluster is “Nervous system”, which in 2014 was 35.93% of the sales rates of the group studied in natural units, and 30.12% – in monetary value (Table 1). Analysis of the ND consumption in the pharmacotherapeutic group B “Blood and blood forming organs” has shown that import drugs are not presented in the ND nomenclature at the Ukrainian pharmaceutical market (Fig. 5, Fig. 6). The analysis showed that in monetary value the growth rates over the period under study

Pharmacotherapeutic subgroup

Findings

Conclusions